dc.creator | Galarce, Gloria D. | |
dc.creator | Foncea, Rocío | |
dc.creator | Edwards, Ana María | |
dc.creator | Pessoa Mahana, Hernán | |
dc.creator | Pessoa Mahana, Carlos David | |
dc.creator | Ebensperger González, Roberto | |
dc.date.accessioned | 2010-01-22T13:32:34Z | |
dc.date.available | 2010-01-22T13:32:34Z | |
dc.date.created | 2010-01-22T13:32:34Z | |
dc.date.issued | 2008 | |
dc.identifier | BIOLOGICAL RESEARCH Volume: 41 Issue: 1 Pages: 43-50 Published: 2008 | |
dc.identifier | 0716-9760 | |
dc.identifier | https://repositorio.uchile.cl/handle/2250/120861 | |
dc.description.abstract | This study describes the effect of novel 6-Arylbenzimidazo[1,2-c]quinazoline derivatives as tumor necrosis factor alpha (TNF-alpha) production inhibitors. The newly synthesized compounds were tested for their in vitro ability to inhibit the lipolysaccharide (LPS) induced TNF-alpha secretion in the human promyelocytic cell line HL-60. The compound 6-Phenyl-benzimidazo[1,2-c]quinazoline, coded as G1, resulted as the most potent inhibitor and with no significant cytotoxic activity. Thus, 6-Arylbenzimidazo[1,2-c]quinazoline derivatives may have a potential as anti-inflammatory agents. | |
dc.language | en | |
dc.publisher | SOC BIOLGIA CHILE | |
dc.subject | ANTITUMOR | |
dc.title | Biological evaluation of novel 6-arylbenzimidazo [1,2-c]quinazoline derivatives as inhibitors of LPS-induced TNF-alpha secretion | |
dc.type | Artículo de revista | |